Identification and Mapping Real-World Data Sources for Heart Failure, Acute Coronary Syndrome, and Atrial Fibrillation
| Autor: | Folkert W. Asselbergs, Richard Dobson, Simrat Gill, Sara Bruce Wirta, Harshul Natani, Claudio Sartini, Dipak Kotecha, R. Agrawal, Rachel Studer, Kiliana Suzart-Woischnik, Spiros Denaxas |
|---|---|
| Přispěvatelé: | Cardiology |
| Rok vydání: | 2021 |
| Předmět: |
Acute coronary syndrome
medicine.medical_specialty Complete data Future studies eCardiology/Digital Health: Systematic Review business.industry Acute Coronary Syndrome/epidemiology Information Storage and Retrieval Atrial fibrillation Comorbidity medicine.disease Identification (information) Heart failure Emergency medicine Atrial Fibrillation/epidemiology medicine Global health Humans Pharmacology (medical) Heart Failure/epidemiology Cardiology and Cardiovascular Medicine business Real world data |
| Zdroj: | Cardiology Cardiology, 147(1), 98-106. S. Karger AG |
| ISSN: | 0735-1097 0008-6312 |
| DOI: | 10.1159/000520674 |
| Popis: | Background: Transparent and robust real-world evidence sources are increasingly important for global health, including cardiovascular (CV) diseases. We aimed to identify global real-world data (RWD) sources for heart failure (HF), acute coronary syndrome (ACS), and atrial fibrillation (AF). Methods: We conducted a systematic review of publications with RWD pertaining to HF, ACS, and AF (2010–2018), generating a list of unique data sources. Metadata were extracted based on the source type (e.g., electronic health records, genomics, and clinical data), study design, population size, clinical characteristics, follow-up duration, outcomes, and assessment of data availability for future studies and linkage. Results: Overall, 11,889 publications were retrieved for HF, 10,729 for ACS, and 6,262 for AF. From these, 322 (HF), 287 (ACS), and 220 (AF) data sources were selected for detailed review. The majority of data sources had near complete data on demographic variables (HF: 94%, ACS: 99%, and AF: 100%) and considerable data on comorbidities (HF: 77%, ACS: 93%, and AF: 97%). The least reported data categories were drug codes (HF, ACS, and AF: 10%) and caregiver involvement (HF: 6%, ACS: 1%, and AF: 1%). Only a minority of data sources provided information on access to data for other researchers (11%) or whether data could be linked to other data sources to maximize clinical impact (20%). The list and metadata for the RWD sources are publicly available at www.escardio.org/bigdata. Conclusions: This review has created a comprehensive resource of CV data sources, providing new avenues to improve future real-world research and to achieve better patient outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|